VIELA BIO, INC. (VIE) News
Filter VIE News Items
VIE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VIE News Highlights
- VIE's 30 day story count now stands at 17.
- Over the past 25 days, the trend for VIE's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about VIE are BIO, MDC and RL.
Latest VIE News From Around the Web
Below are the latest news stories about Viela Bio Inc that investors may wish to consider to help them evaluate VIE as an investment opportunity.
AstraZeneca to supply U.S. with extra 500,000 doses of COVID-19 antibody-based cocktailAZD7442 is being evaluated for the prevention and treatment of COVID-19 in late-stage trials in more than 9,000 participants around the world. |
Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc.Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has completed the acquisition of Viela Bio, Inc. (Nasdaq: VIE) (“Viela”). “The Viela a |
ALERT: Halper Sadeh LLP Investigates VIE, CMD, COHR, PRSP; Shareholders are Encouraged to Contact the FirmNEW YORK, March 4, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Viela Bio, Inc. (NASDAQ: VIE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to… |
Viela Bio (NASDAQ:VIE) Posts Earnings ResultsViela Bio (NASDAQ:VIE) released its quarterly earnings results on Sunday. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.10, MarketWatch Earnings reports. Shares of Viela Bio stock remained flat at $$52.93 during trading on Tuesday. 381,910 shares of the stock traded hands, compared to its average volume of […] |
Lifshitz Law Firm, P.C. Announces Investigation of MDCA, PRSP, PROS, and VIENEW YORK, NY / ACCESSWIRE / March 1, 2021 / MDC Partners Inc. (NASDAQ:MDCA)Lifshitz Law Firm, P. |
SHAREHOLDER ALERT: Halper Sadeh LLP Continues to Investigate WIFI, CHNG, CUB, VIE; Shareholders Are Encouraged to Contact the FirmNEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Boingo Wireless, Inc. (NASDAQ: WIFI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to an affiliate of Digital Colony Management, LLC for $14.00 per share in cash. If you are a Boingo shareholder, click here to learn more about your rights and options. Change Healthcare Inc. (NASDAQ: CHNG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Optum, a company that is part of UnitedHealth Group. Under the merger agreement, Change Healthcare shareholders will receive $25.75 per share in cash. If you are ... |
Recap: Viela Bio Q4 EarningsShares of Viela Bio (NASDAQ:VIE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 36.17% year over year to ($0.60), which beat the estimate of ($0.70). Revenue of $9,336,000 declined by 68.88% from the same period last year, which beat the estimate of $5,550,000. Outlook Viela Bio hasn't issued any earnings guidance for the time being. View more earnings on VIE Revenue guidance hasn't been issued by the company for now. Technicals 52-week high: $70.66 Company's 52-week low was at $25.02 Price action over last quarter: Up 50.07% Company Overview Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its ... |
SHAREHOLDER ALERT: WeissLaw LLP Reminds CRHM, VIE, PROS, and EXPC Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial ResultsGAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for patients suffering from autoimmune and severe inflammatory diseases, today reported financial results and provided program and business highlights for the fourth quarter and full year ended December 31, 2020. “2020 was a year of great progress for Viela, despite the many external challenges resulting from the COVID-19 global pandemic,” said Bing Yao, Ph.D., Chief Executive Officer at Viela Bio. “Most significantly, we received FDA approval for UPLIZNA® to treat adult patients with AQP4+ NMOSD and achieved solid product uptake, closed a successful public offering and continued to advance our full pipeli... |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, VIE, CLGX, CRHM; Shareholders Are Encouraged to Contact the FirmNEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: MDC Partners Inc. (NASDAQ: MDCA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Stagwell Media LP. Stagwell and its affiliates are expected to hold approximately 79% of the common equity of the combined company after closing. If you are an MDC shareholder, click here to learn more about your rights and options. Viela Bio, Inc. (NASDAQ: VIE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Horizon Therapeutics plc for $53.00 per share in cash. If you are a Viela Bio shareholder, click here to... |